Introduction. Since the discovery of Streptomycin, an increasing effort has been devoted to the development of new and more efficient anti-tubercular agents, leading to the introduction of a number of new molecules in clinical practice [1 – 12]. Nevertheless the growth of multi-drug resistant mutant species of mycobacterium (MDR) has become an emerging problem [13], in spite of the fact that M. tuberculosis was one of the first infective agents whose genome was ...